

CURRICULUM VITAE

NAME: Kenneth H. Rand, M.D.
Professor of Pathology and Medicine
University of Florida, College of Medicine
Gainesville, FL 32610
Ph: 352-265-9919
Fax: 352-265-0447

EDUCATION: B.A., Biology, Cum Laude, Harvard College, Cambridge, MA, 1964

M.D., Stanford University, School of Medicine, Stanford, California, 1969

Intern in Medicine, Stanford University, Stanford, California, 1969-1970

1st Year Resident (Medicine), Stanford University, Stanford, California,
1970-1971

2nd Year Resident (Medicine), Stanford University Hospital (On leave of
absence from Infectious Disease Fellowship) Stanford, California, 1/76-
6/76

Fellowship, Division of Infectious Diseases, Stanford University,
Stanford, California (with Dr. Thomas C. Merigan), Stanford, California,
7/74-6/77

APPOINTMENTS: Research Associate, Viral Carcinogenesis Branch, National Cancer
Institute, National Institute of Health, Bethesda, MD, 1971-1974

Assistant Clinical Instructor of Medicine, Department of Medicine,
George Washington University Medical School, Washington, D.C., 1971-
1974

Assistant Professor of Medicine, Division of Infectious Diseases,
Departments of Medicine, Pathology and Immunology and Medical
Microbiology, University of Florida College of Medicine and the
Gainesville Veterans Administration Hospital, Gainesville, FL, 8/77-8/82

Acting Chief, Division of Infectious Diseases, Department of Medicine,
University of Florida, Gainesville, FL, 7/80-1/81

Hospital Epidemiologist (Acting) together with Drs. Ramphal and Shands,
J.W., Shands Teaching Hospital, Gainesville, FL, 8/80-6/82

Associate Professor of Medicine, Division of Infectious Diseases,
Departments of Medicine, Pathology and Immunology and Medical
Microbiology, University of Florida, Gainesville, FL, 9/82-6/84

Associate Professor of Pathology and Medicine (Division of Infectious
Diseases), University of Florida, Gainesville, FL, 7/84-6/30/92

Professor of Pathology and Medicine (Division of Infectious Diseases)
University of Florida, Gainesville, FL 7/92-Present

Director, Diagnostic Virology Laboratory, Shands Hospital, University of
Florida, Gainesville, FL, 8/77-Present

Director, Microbiology Laboratory, Shands Hospital, University of
Florida, Gainesville, FL, 7/84-Present

Director, Microbiology Laboratory, Gainesville Veterans Administration
Medical Center, Gainesville, FL, 7/84- 6/98

Acting Medical Director, Shands Hospital Laboratories, University of
Florida, Gainesville, FL, 7/89-6/90

Chief, Clinical Pathology, Department of Pathology, University of
Florida, Gainesville, Fl, 1989 - Present

Medical Director, Shands Hospital Laboratories, University of
Florida, Gainesville, Fl, 1990 - Present

Medical Director, Shands at Alachua General Hospital, Gainesville, Fl.,
2008 - 2009

FDA Microbiology Devices Advisory Panel, 2009 - present

CURRENT COMMITTEE RESPONSIBILITIES:

Medical Care Evaluation Committee, 1978-1979

Medical Records Committee, 1978-1980

Infection Control Committee (VAH), 1978-1997
(Chairman 1994- 1997)

Infection Control Committee (STH), 1979-Present

Clinical Research Committee, 1979-1988

Graduate Education Committee (Pathology), 1979-1983

Resident Committee (Pathology), 1984-1988

Quality Assurance Committee (Pathology), 1986-Present

VA Grant Review Committee, 1986-1996

Phase A Committee (Pathology), 1987-1990

Emergency Room Committee, 1988-1991

Executive Committee, Department of Pathology, 1989-Present

Section Chief Committee, 1989-1997

Clinical Unit Chief's Committee, 1989-Present

Referral Laboratory Review Committee, 1989-1996

Laboratory Advisory Committee, 1988-Present

College of Medicine Teaching Physicians Compliance Implementation
Committee, 1997 - Present

Anti-Infective Committee (Subcommittee of the Pharmacy and
Therapeutics Committee), Shands Hospital, 1999 - present

Bioterrorism Committee (Shands Hospital), Subcommittee of the Infection
Control Committee, Chairman, 1998 – present

Laboratory Utilization Committee, Chairman, 2000 – present

Clinic Medical Director's Committee – ad hoc representative for the
laboratory, 1999 - present

Committee on Variable Compensation for Faculty (Department of
Pathology)

Bioterrorism Research Task Force (Health Center), 2002 - present

HONORS AND AWARDS:

None

Kenneth H. Rand, M.D.
Curriculum Vitae
Page 4

BOARDS:

American Board of Internal Medicine, 1976
Infectious Diseases Subspecialty Boards, 1978
American Board of Pathology - Special Certification in Medical Microbiology, 1997

SOCIETY MEMBERSHIPS:

American Association for the Advancement of Science
American Society for Microbiology
American Society of Clinical Pathology
Alachua County Medical Society
American Association of Pathologists
Infectious Diseases Society of America
Clinical Laboratory Management Association

EDITORIAL BOARDS:

None

SCIENTIFIC REVIEWER:

Archives of Internal Medicine
Clinical Infectious Diseases
Chest

GRANT SUPPORT:

Sharklet Technologies, Inc., Alachua, FL
Effect of the Sharklet micro-topography on survivability of bacteria on surfaces
P.I. Kenneth H. Rand, M.D.
Funding period: November, 2008 - October, 2009
Total Award: \$11,875

Cepheid
GeneXpert Study of Group B Streptococcus
P.I. Rodney Edwards, M.D.
Co P.I.: Kenneth H. Rand, M.D.
Funding period: 10/05 – 9/08
Total Award: \$3,750

Cubist Pharamceuticals

Title: Daptomycin Synergy Study
P.I. Kenneth H. Rand, M.D
Funding period: 5/02 – 5/09
Total Award: \$80,000

Biogen, Inc.

Title: Clinical Study of EBNA-1 Associated Oligoclonal Bands
Effort: 5%
P.I. Kenneth H. Rand, M.D.
Funding Period: 12/98 - 2000
Total Award: \$3,000

National Multiple Sclerosis Society

Title: Identification of Oligoclonal Bands in Multiple Sclerosis
Effort: 25%
P.I.: Kenneth H. Rand, M.D.
Funding Period: 10/1/95 – 9/30/02
Total Award: \$223,000

Cook Instrument Company

Title: Untunneled Central Venous Catheters Impregnated With Minocycline and Rifampin Vs Tunneled Uncoated Catheters: Comparison of Rates of Catheter Colonization and Catheter-Related Bloodstream Infection
Effort: 5%
P.I.: Rabih Darouiche, M.D. Baylor College of Medicine, Houston, Tx
Co P.I.: Kenneth H. Rand, M.D.
Funding Period: 1999-2001
Total Award: \$20,000

VA Cooperative Study 448

Title: A Randomized, Controlled, Blinded, Multicenter Trial to Assess the Efficacy of Protection from Natural Influenza Virus Infection of Influenza Virus Vaccine, Trivalent, Types A and B, Live, Cold Adapted (CAIV-T), and Inactivated Influenza Virus Vaccine in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Field Trial
Effort: 1 %
P.I.: Runi Foster, M.D.
Consultant: Kenneth H. Rand, M.D.
Funding Period: 1999
Total Award: \$2,000

Pall Biomedical Products

Title: Does Carbon Dioxide Absorbent Contaminated with Bacterial and Mycobacterial Agents Put patients At Risk for Pulmonary Infections During and After Anesthesia

Effort: 5%

P.I.: Joseph Layon M.D.

Co P.I.: Kenneth H. Rand M.D.

Funding Period: 1994 - 1997

Total Award: \$48,400 (Dr. Rand's portion - \$5,000)

Cook Instrument Company

Title: The Efficacy of Central Venous Catheters Impregnated with Minocycline and Rifampin vs Catheters Bonded with Chlorhexidine and Silver Sulfadiazine in the Reduction of Catheter Infection

P.I.: Rabih Darouiche, M.D. Baylor College of Medicine, Houston, Tx

Co P.I.: Kenneth H. Rand, M.D.

Funding period: 1996 - 1998

Total Award: Dr. Rand's portion \$15,000

Abbott Laboratories

Title: Evaluation of the Abbott LcX (Ligase Chain Reaction) compared with the Roche Amplicor (PCR) method for the detection of genital Chlamydia infection

PI: Kenneth H. Rand, M.D.

Funding Period: May 1, 1996 - April 30, 1998

Total Award: \$5,000

PUBLICATIONS:

1. *Yalom, I. and **Rand, K.H.**: Compatibility and cohesiveness in therapy groups. Archives of Gen. Psych. 1966, Volume 15, pp. 267-275.
2. *Yalom, I.; Houts, P.; Zimmerberg, S. and **Rand, K.H.**: Prediction of improvement in group therapy. Arch. Gen. Psych. 1967, Volume 17, pp. 159-168.
3. *Yalom, I.; Houts, P.; Newell, G. and **Rand, K.H.**: Preparation of patients for group therapy. Arch. Gen. Psych. 1967, Volume 17, pp. 416-427.
4. ***Rand, K.H.** and Long, C.A.: Syncytial assay for the putative human C-type virus RD 114, utilizing human cells transformed by Rous sarcoma virus. Nature, New Biol. 1972, Volume 240, pp. 187-190.
5. *Hamper, G.; **Rand, K.H.**; Lerner, R.; Del Villano, B.C.; McAllister, R.M.; Martos, L.M.; Dere, J.G.; Long, C.W. and Gilden, R.V.: Formation of syncytia in human lymphoblastoid cells infected with type C viruses. Virology 1973, Volume 55, pp. 453-463.

6. ***Rand, K.H.** and Long, C.W.: Fusion of a Rous Sarcoma virus transformed human cell line, KC by RD 114 virus. J. Gen. Virology 1973, Volume 21, pp. 523-532.
7. *Rubio, V.; Tsai, W.P.; **Rand, K.H.** and Long, C.: A comparison of DNA binding proteins from normal and virus-transformed mouse cells. Int. J. CA 1973, Volume 12, pp. 545-550.
8. *Long, C.W.; Good, E.; Gilden, R.V. and **Rand, K.H.**: Murine sarcoma virus induced cytopathological effect in mouse cells made resistant to 6-Azauridine. J. Gen. Virology 1974, Volume 23, pp. 185-189.
9. ***Rand, K.H.**; Long, C.W.; Wei, T.T. and Gilden, R.V.: Plaque assay for the Mason-Pfizer monkey virus. J. Nat. CA Inst. 1974, Volume 53, pp. 449-452.
10. ***Rand, K.H.**; Davis, J.; Gilden, R.V.; Oroszlan, S. and Long, C.W.: Fusion inhibition: Bioassay of a type C viral protein. Virology 1975, Volume 64, pp. 63-74.
11. ***Rand, K.H.**; Reed, B.; Broseus, K.; Hampar, B.; Gilden, R.V. and Long, C.: Mixed-culture cytopathogenicity between KC and XC Oncornavirus indicator lines and "virus-free" human choriocarcinoma cells. J. Natl. Cancer Inst. 1976, Volume 56, pp. 509-512.
12. ***Rand, K.H.**; Emmons, R.W. and Merigan, T.C.: Adult measles: An unforeseen consequence of immunization? JAMA 1976, Volume 236, pp. 1028-1031.
13. ***Rand, K.H.**; Johnson, K.P.; Rubenstein, L.J.; et al.: Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy. Use of Urine cytology to assess response to therapy. Annals of Neurology 1977, Volume 1, pp. 458-462.
14. ***Rand, K.H.**; Rasmussen, L.E.; Pollard, R.B.; Arvin, A. and Merigan, T.C.: Cellular immunity and herpes virus infections in cardiac transplant patients. New Engl. J. Med. 1977, Volume 296, pp. 1372-1377.
15. *Pollard, R.B.; **Rand, K.H.**; Arvin, A. and Merigan, T.C.: Cell mediated immunity to cytomegalovirus infection on normal persons and cardiac transplant recipients. J. Infect. Dis. 1978, Volume 137, pp. 541-549.
16. ***Rand, K.H.**; Pollard, R.B. and Merigan, T.C.: Increased pulmonary superinfections in cardiac transplant patients undergoing primary cytomegalovirus infection. New Engl. J. Med. 1978, Volume 298, pp. 951-953.
17. *Merigan, T.C.; **Rand, K.H.**; Pollard, R.B.; Abdallah, P.S.; Jordan, G.W. and Fried, R.P.: Administration of human leukocyte interferon in herpes zoster: II Preliminary controlled trials to establish effective dosage in patients with malignancy. New Engl. J. Med. 1978, Volume 298, pp. 981-987.

18. ***Rand, K.H.**: Isolation of herpes simplex virus type-1 from gastric contents of a patient with acute pancreatitis. South Med. J. 1981, Volume 74, pp. 489-491.
19. ***Rand, K.H.**; Rosenbloom, A.L.; Maclaren, N.K.; Silverstein, J.H.; Riley, W.J.; Butterworth, B.; Yoon, J.W.; Rubenstein, A.H. and Merigan, T.C.: Human leukocyte interferon treatment of two children with insulin dependent diabetes. Diabetologia 1981, Volume 21(2), pp. 116-119.
20. *Landis, S.J.; Ramphal, R.; Mansheim, B.J.; **Rand, K.H.** and Shands, J.W., Jr.: Comparative efficacy of Piperacillin and Penicillin G in the treatment of Gonococcal Urethritis. Antimicrob. Agents Chemother. 1981, Volume 20, pp. 693-695.
21. ***Rand, K.H.**; Kramer, B. and Johnson, T.: Cancer chemotherapy associated symptomatic stomatitis: Role of herpes simplex virus (HSV). Cancer 1982, Volume 50, pp. 1262-1265.
22. *Pollard, R.B.; Arvin, A.M.; Gamberg, P.; **Rand, K.H.**; Gallagher, J.G. and Merigan, T.C.: Specific cell mediated immunity and infections with cytomegalovirus, herpes simplex virus and varicella-zoster virus in cardiac transplant recipients. Amer. J. Med. 1982, Volume 73(5), pp. 679-687.
23. *Ramphal, R.; Kramer, B.S.; **Rand, K.H.**; Weiner, R.S. and Shands, J.W.: Early results of a comparative trial of ceftazidime versus cephalothin carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. J. Anti Chem. 1983, Volume 12, pp. 81-88.
24. ***Rand, K.H.**; Jacobson, D.G.; Cottrell, C.R.; Koch, K.L.; Guild, R.T. and McGuigan, J.E.: Antibodies to herpes simplex type I in patients with active duodenal ulcer. Arch. Intern Med 1983, Volume 143:1917-1920.
25. *Kramer, B.; Carr, D.; **Rand, K.H.**; Pizzo, P.; Johnson, A.; Robichaud, K. and Yucha, J.: Prophylaxis of fever and infection in adult cancer patients: A placebo-controlled trial of oral trimethoprim- sulfamethoxazole plus erythromycin. Cancer 1984, Volume 53, pp. 329-335.
26. ***Rand, K.H.**; Rayfield, M.A. and Berns, K.I.: Recovery of herpes simplex type-1 from the celiac ganglion of a renal transplant patient. Southern Med J. 1984, Volume 77, pp. 403-404.
27. *Gotz, V.P.; **Rand, K.H.** and Kramer, B.S.: Effect of filtering amphotericin B infusions on the incidence and severity of phlebitis and selected adverse reactions. Drug Intelligence & Clin. Phar. 1985, Volume 19, pp. 436-439.

28. ***Rand, K.H.**; Houck, B.S. and Swingle, H.M.: Rotazyme Assay in Neonates without Diarrhea. Am J Clin Path. 1985, Volume 84, pp. 748-751.
. Internal Med. 1983, Volume 143, pp. 1 917-1920.
29. *Oblon, D.J.; Elfenbein, G.J.; **Rand, K.H.** and Weiner, R.S.: Recurrent Varicella-Zoster Infection After Acyclovir Therapy in Immunocompromised Patients. Southern Med J. 1986, Volume 79, pp. 256-257.
30. ***Rand, K.H.**, Bodor, N., El Koussi, A.A., Raad, I., Miyake, A., Houck, H. and Gildersleeve, N.: Potential treatment of Herpes Simplex Virus Encephalitis by Brain-Specific Delivery of Trifluorothymidine using a Dihydropyridine Pyridinium Salt Type Redox Delivery System. J. Med. Virology. 1986, Volume 20, pp. 1-8.
31. ***Rand, K.H.**, Houck, H.J. and Dickinson, M.: False Positive Indirect Fluorescent Antibody (IFA) Tests for Antibody to Herpes Simplex Virus -1 (HSV-1): Comparison of Four Commercially Available Methods. Am. J. Clin. Path. 1986, Volume 86(6), pp. 765-768.
32. *Kramer, B.S., Ramphal, R. and **Rand, K.H.**: A Randomized Comparison of Two Ceftazidime-Containing Regimens versus Cephalothin-Gentamicin-Carbenicillin in Febrile Granulocytopenic Cancer Patients. Antimicrob. Agents Chemother. 1986, Volume 30(1), pp. 64-68.
33. ***Rand, K.H.**, Raad, I., El Koussi, A.A., Houck, H., Brey, W., Rocca, J.; Loftsson, T.; and Bodor, N.: Trifluorothymidine: potential non-invasive diagnosis of herpes simplex using ¹⁹F nuclear magnetic resonance in a murine hepatitis model. J. Virological Methods, 1987, Volume 18, pp. 257-270.
34. *Elfenbein, G.J., Krischer, J.P., **Rand, K.H.**, Graham-Pole, J., Babington, R.G.: Prevention of cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation: A multicenter trial. Clinical Immunol Newsletter, 1099. Volume 9, pp. 203-205.
35. *Elfenbein, G., Krischer, J., Babington, R., Hong, R., Jansen, J., Lazarus, H., Winton, E. and **Rand, K.**: Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation. Transplantation Proceedings 1989, Volume 21, 3099-3100.
36. ***Rand, K.H.**, Houck, H., Ganju, A., Babington, R.G. and Elfenbein, G.J.: Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplantation, 1989, Volume 4, pp. 679-683.

37. *Sherertz, R.J., Raad, I.I., Belani, A., Koo, L.C., **Rand, K.H.**, Pickett, D.L., Straub, S.A. and Fauerbach, L.L.: Three year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory. J. Clin. Micro., 1989, Volume 28, pp. 76-82.
38. ***Rand, K.H.**, Hoon, E.F., Massey, J.K. and Johnson, J.H.: Daily stress and recurrence of genital herpes simplex. Archives of Int. Med. 1990, Volume 150, 1889-1893.
39. *Johnson, M.P. and **Rand, K.H.**: Group A -streptococcal bacteremia and HIV infection. S Med Journal, 1990, Volume 83, pp. 146-149.
40. ***Rand, K.H.** and Houck, H.: Taq polymerase contains bacterial DNA of unknown origin. Mol Cell Probes, 1990, Volume 4, 445-450.
41. *Raad, I., **Rand, K.H.** and Gaskins, D.: Buffered charcoal-yeast extract medium for the isolation of *Brucellae*. J. Clin Micro., 1990, Volume 28, pp. 1671-1672.
42. *Elfenbein, G.J., Siddiqui, T., **Rand, K.H.**, Graham-Pole, J., Marcus, R.B., Mendenhall, N.P., Goedert, T.M., Wikle-Fisher, T., Gross, S.A., and Weiner, R.S.: Successful strategy for prevention of cytomegalovirus interstitial pneumonia after human leukocyte antigen-identical bone marrow transplantation. Rev Infect Dis. 1990, Volume 12(Suppl. 7), pp. S805-S810.
43. *Hoon, E.F., Hoon, P.W., **Rand, K.H.**, Johnson, J., Hall, N.R., and Edwards, N.B.: A Psycho-Behavioral Model of Genital Herpes Recurrence. J Psychosom Res. 1991, Volume 35(1), pp. 25-36.
44. *Judson, F.N., Eron, L.J., Lutz, F.B., **Rand, K.H.**, Tennican, P.O. and Mogabgab, W.J.: Multicenter study of a single 500-mg dose of cefotaxime for treatment of uncomplicated gonorrhea. Sex Transm Dis. 1991, Volume 18(1), pp. 41-43.
45. *Krischer, J., Elfenbein, G., Babington, R., Hong, J., Jansen, H., Lazarus, H., Winton, E. and **Rand, K.H.**: Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin. Sem Hematol. 1992, Volume 29(3), pp. 89-95.
46. *Ramphal, R., Bolger, M., Oblon, D.J., Sherertz, R.J., Malone, J.D., **Rand, K.H.**, Gilliom, M., Shands, Jr., J.W., and Kramer, B.S.: Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving Ceftazidime: a randomized prospective study. Antimicro Agents & Chemotherapy. 1992, Volume 36(5), pp. 1062-1067.
47. *Raad, I.I., Sabbagh, M.F., **Rand, K.H.**, Sherertz, R.J.: Quantitative Tip Culture Methods and the Diagnosis of Central Venous Catheter-Related Infections. Diagn Microbiol Infect Dis. 1992, Volume 15, pp. 13-20.

48. ***Rand, K.H.**, Gibbs, K., Derendorf, H., and Graham-Pole, J.: Pharmacokinetics of Intravenous Immunoglobulin (Gammagard^R) in Bone Marrow Transplant Patients. J. Clin. Pharmacol., 1991, Volume 31(12), 1151-1154.
49. *Ramphal, R., Bolger, M., Oblon, D.J., Sherertz, R.J., Malone, J.D., **Rand, K.H.**, et al.: Vancomycin is Not an Essential Component of the Initial Empiric Treatment Regimen for Febrile Neutropenic Patients Receiving Ceftazidime: a Randomized Prospective Study. Antimicrobial Agents and Chemotherapy, 1992, 1992, Volume 36(5), 1062-1067.
50. **Rand, K.H.**, Houck, H.J., Brown, P. and Bennet D.: Reproducibility of the Microdilution Checkerboard Method for Antibiotic Synergy. Antimicrobial Agents and Chemotherapy, March 1993, 37(3), 613-615.
51. Wolff, M.A., **Rand, K.H.**, Houck, H.J., Brunson, M.E., et al.: Relationship of the Polymerase Chain Reaction for Cytomegalovirus to the Development of Hepatitis in Liver Transplant Recipients. Transplantation, 1993, 56 (3), 572-576.
52. **Rand, K.H.**, Houck, H.J. and Wolff, M.: Detection of Candidemia by Polymerase Chain Reaction. Molecular Cell Probes, 1994, 8 (3) 215-221.
53. **Rand, K.H.** and Brown P.: Concentration-Dependent Synergy and Antagonism Between Cefoperazone and Imipenem Against Methicillin-Resistant Staphylococcus Aureus. Antimicrobial Agents and Chemotherapy, 1995, 39 (5) 1173-1177.
54. Nolting, A., Costa, T.D., **Rand, K.H.** and Derendorf, H.: Pharmacokinetic-Pharmacodynamic Modeling of the Antibiotic Effect of Piperacillin in Vitro. Pharm Res, 1996, Volume 13, pp 91-96.
55. Nolting, A., Costa, T.D., Vistelle, R., **Rand, K.H.** and Derendorf, H.: Determination of Free Extracellular Concentrations of Piperacillin by Microdialysis. J Pharm Sci, 1996, 85 (4) 369-372.
56. **Rand, K.H.**: Rejection Criteria for Endotracheal Aspirates in Neonates: Clinical Impact. Diagn Microbiol Infect Dis, 1997;27:55-61.
57. Al-Abbadi, M., Wolff, M., **Rand K.H.**, Baer H.: Invasive Aspergillosis Preceded by Legionella Pneumonia: A Report of Two Cases and Review of the Literature. J Histotechnol 1997;20:371-373.
58. **Rand, K.H.**, Houck, H, Denslow, N.D., Heilman, K.M.: Molecular Approach to Find Target(s) for Oligoclonal Bands in Multiple Sclerosis. J Neurol Neurosurg Psych. 1998;65:48-55.

59. Davis, J.D., Riley, P.K., Peters, C. and **Rand K.H.**: A Comparison of Ligase Chain Reaction to Polymerase Chain Reaction in the Detection of *Chlamydia trachomatis* Endocervicitis. Infect Dis Obstet Gynecol 1998;6:57-60.
60. Mehta, J.L, Saldeen, T. G. P., **Rand, K.H.** Interactive Role of Infection, Inflammation, and Traditional Risk Factors in Atherosclerosis and Coronary Artery Disease. J Am Coll Card. 1998 6;1217-25.
61. Langevin, P.B., Layon, A.J., **Rand, K.H.**, Banner, M.J., Langevin, S.O.: Dissemination of *Mycobacterium Tuberculosis* Through Anesthesia Breathing Circuits. Chest 1999 155 (4) 1107-1114.
62. **Rand, K.H.**, Houck, H, Denslow, N.D., Heilman, K.M. Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) Associated Oligoclonal Bands in Patients with Multiple Sclerosis. J Neurol Sci 2000 173:32-39.
63. **Rand, K.H.**, Houck, H.: Improved Methods for the Application of Random Peptide Phage Libraries to the Study of the Oligoclonal Bands in Cerebrospinal Fluid of Patients with Multiple Sclerosis. J. Neurol Sci. 2000 101:131-139.
64. Netzel, T. and **Rand, K.** Prostatitis Associated with *Corynebacterium glucuronolyticum*. Clin Micro News 24:94-95, 2002.
65. **Rand, K.H.** and Houck, H.: Daptomycin Synergy with Rifampicin and Ampicillin Against Vancomycin-Resistant Enterococci. J Antimicrob Chemother. 2004;53:530-532.
66. de la Peña, A., Gräbe, A., **Rand, K. H.**, Rehak, E., Gross, J., Thyroff-Friesinger, U., Müller, M., and Derendorf, H. PK-PD Modelling of the Effect of Cefaclor on Four Different Bacterial Strains. Int J Antimicrob.Agents 2004;23(3):218-25.
67. Liu, Q., **Rand, K.**, Derendorf, H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 2004, 23:494-497.
68. **Rand, K.H.**, Houck, H.J. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2004, 48:2871-2875.
69. Grier, D.D., Qiu, J., **Rand, K.**, Donnelly, W.H. Pathologic quiz case: a 13-year-old boy with a 2-day history of fever, vomiting, and mental status changes. *Chromobacterium violaceum* bacteremia. Arch Pathol Lab Med 2004, 128:e131-e132.
70. Liu, P., **Rand, K.H.**, Obermann, B., Derendorf, H. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 2005, 25:120-129.

71. **Rand, K.H.**, Houck, H. J., Lawrence, R. M. Real-Time Polymerase Chain Reaction of Herpes Simplex Virus in Cerebrospinal Fluid and Cost Savings from Earlier Hospital Discharge. J Mo Diagn 2005, 7;511-516.
72. Tillan, Maria and **Rand, K.H.** Errors in Interpretation of Gram's Stains from Positive Blood Cultures. Am J Clin Pathol 2006, 686-690.
73. Netzel, T. Jindani., Hanson, N. Turner, B.M., Smith, L., **Rand, K.H.** The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli. Diagn Microbiol Infect Dis 2007, 345-348.
74. **Rand, K.H.**, Houck, H.J., Silverman, J.A. Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium. J. Antimicrob Chemother 2007 59(5):1017-20.
75. Treyaprasert W., Schmidt S., **Rand K.H.**, Suvanakoot U., Derendorf H. Pharmacokinetic pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents. 2007 Mar; 29(3):263-70.
76. Clancey, C.J., Jaber, R.A., Leather, H.S., Wingard, J.R., Staley, B., Wheat, L.J. Cline, C.L, **Rand, K.H.**, Schain, D., Baz, M., Nguyen. M.H. Bronchoalveolar Lavage Galactomannan in Diagnosis of Invasive Pulmonary Aspergillosis among Solid-Organ Transplant Recipients. J Clin Microbiol. 2007 Jun; 45(6):1759-65.
77. Nguyen,M.H., Jaber,R., Leather,H.L., Wingard,J.R., Staley,B., Wheat,L.J., Cline,C.L., Baz,M., **Rand, K. H.**;Clancy,C.J. Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol 2007; 45: 2787-2792.
78. Schmidt, S., Banks, R., Kumar, V., **Rand, K.H.**, Derendorf, H. Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol. 2008 Mar;48(3):351-64.
79. Archibald, L.K., Shapiro, J. Pass, A., **Rand K.H.**, Southwick F. Methicillin-resistant Staphylococcus aureus infection in a college football team: risk factors outside the locker room and playing field. Infect Control Hosp Epidemiol. 2008 May;29(5):450-3
80. Schmidt, S., Barbour A., Sahre M., **Rand K.H.**, Derendorf, H. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol. 2008 Oct;8(5):549-56.
81. Cardona, D. and **Rand, K. H.** Evaluation of repeat Clostridium difficile enzyme immunoassay testing. J. Clin Micro 2008 Nov;46(11):3686-9.
82. Barbour, A. Schmidt, S., **Rand, K.H.**, Derendorf, H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2009.

83. Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, Derendorf H. Clinical pharmacokinetics and pharmacodynamics of tigecycline. *Clin Pharmacokinet.* 2009;48(9):575-84.

NATIONAL PRESENTATIONS:

1. **Rand, K. H.** Using Rapid Methods for Positive Blood Cultures to Improve Patient Care. Convener for Symposium 077/C. How to be Proactive in Clinical Microbiology to Improve Patient Outcomes. The American Society of Microbiology, Orlando, Florida, May 2006.
2. **Rand K.**, Houck H., Gaskins D., Pittman L., Prins C., Fauerbach L., Seifert H., and Gross M. Spread of KPC Carbapenemase-producing *K. pneumoniae* to North Florida. Association for Molecular Pathology, November, 2007.

REGIONAL PRESENTATIONS

1. **Rand, K. H.** Current Issues in Resistance Testing: ESBLs, the D Test and More, Dade Days, Orlando, FL September, 2006
2. **Rand, K. H.** Current Issues in Resistance Testing: ESBLs, the D Test and More, Dade Days, Deerfield Beach, FL September, 2006
3. **Rand, K. H.** Molecular Methods in Medicine: PCR and Post-PCR Polk County Medical Society October 17, 2007

PUBLICATIONS SUBMITTED OR IN PRESS:

1. Russo, J., Rusiecki R., Vincek V., and **Rand K.H.** Purpuric Eruption in a Patient Treated with Systemic Steroids - Quiz Case (In Press)
2. Anton, A. and **Rand, K.H.** Subpopulations of Antibiotic Resistant *Pseudomonas aeruginosa* in Sputum of Cystic Fibrosis Patients. (Submitted)

BOOKS - CHAPTERS:

1. **Rand, K.H.** and Balfour H.J., Jr.: "Laboratory Diagnosis of Infections". In: *Surgical Infectious Diseases.* Appleton and Lang, Press, Norwalk, Connecticut, 1988, Chapter 15, pp. 247-257.
2. **Rand, K.H.** "CNS Infections" In: *Textbook of Neuro Intensive Care.* (Eds. A. Joseph Layon, M.D., Andrea Gabrielli, M.D. and William Friedman, M.D) W.B. Saunders, NY, NY., 2004, Chapter 12, pp. 337-396.

ABSTRACTS:

1. **Rand, K.**, Eastman, P. and Schrier, S.L.: Chloramphenicol effect on mouse erythroid spleen colonies. Clinical Research 1968, Volume 16, pp. 124.
2. **Rand, K.H.**, Emmons, R.W. and Merigan, T.C.: Adult measles: An unforeseen consequence of immunization? Clinical Research 1976, Volume 24, pp. 114A.
3. Pollard, R.B.; **Rand, K.H.**; Arvin, A.M. and Merigan, T.C.: Impaired specific cellular immunity (CI) in cytomegalovirus (CMV) infected cardiac transplant (CTX) recipients. 17th International Conference on Antimicrobial Agents and Chemotherapy, New York, October 1977.
4. Boysen, P.G.; **Rand, K.H.**; Jenkins, R.T. and Murphy, E.J.: Relationship of serial gram stains and cultures of tracheal aspirates to nosocomial pneumonia. Crit. Care Med. 1979, 7, pp. 142.
5. Berns, K.I.; Rayfield, M.; Hauswirth, W.W. and **Rand, K.H.**: Detection of HSV-1 nucleotide sequences in human trigeminal ganglia. 1st Ames-Yisum Virology Conference on: Latent and persistent virus infections in man. Jerusalem, Israel, 14-18.
6. Rayfield, M.; **Rand, K.**; Hauswirth, W. and Berns, K.I.: HSV nucleotide sequences in latently infected human ganglia. 3rd Annual Cancer Research Seminar, University of South Florida, Tampa, Florida, February 9, 1980.
7. Rayfield, M.; Hauswirth, W.; **Rand, K.** and Berns, K.I.: HSV nucleotide sequences in latently infected human ganglia. International Conference on Human Herpes viruses, Emory University, Atlanta, Georgia, March 17-21, 1980.
8. Riley, W.; Maclaren, N.; **Rand, K.** and Bejar, R.: Inherited autoimmunity versus Cocksackie B4 in insulin dependent diabetes. Diabetes 1980, Volume 29, pp. 53A.
9. **Rand, K.**; Kramer, B.; Garcia, T. and Weiner, R.: Symptomatic stomatitis due to herpes simplex virus (HSV) in patients receiving cytotoxic chemotherapy (CCT). 20th International Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1980.
10. Pollard, R.B.; Arvin, A.M.; Gamberg, P.; **Rand, K.H.**; Gallagher, J.G. and Merigan, T.C.: A prospective study of cell mediated immunity (CMI), and infections with Cytomegalovirus (CMV), herpes simplex virus (HSV) and varicella-zoster virus (VZV) in cardiac transplant (CTx) recipients. 20th International Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1980.

11. **Rand, K.**; Jacobson, D.; Cottrell, R.; Guild, R.; Koch, K. and McGuigan, J.: Relationship of herpes simplex virus type-1 (HSV-1) infection to peptic ulcer disease (PUD). Clinical Research 1981, Volume 29, pp. 824A.
12. Carr, D; Kramer, B.; **Rand, K.**; Pizzo, P. and Johnson.: Oral antibiotic fever prophylaxis in neutropenic adult cancer patients (Pts). Proc. of Amer. Soc. of Clin. Onc. 1982, Volume 1, pp. 58.
13. **Rand, K.H.**; Mahoney, J.J. and Howard, R.J.: Very short incubation Non A Non B (NANB) Hepatitis (HEP) among renal transplant (RTx) patients. American Federation for Clinical Research, New Orleans, LA, January 1983.
14. Sullivan, M.L.; Sherertz, R.J.; Russell, B.A.; **Rand, K.H.**; Herman, K. and Gutekunst, R.R.: Pseudo-outbreak of nosocomial rubella due to false positive IgM serology. 83rd Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, March 1983.
15. Kramer, B.; Jones, J.; Ramphal, R.; **Rand, K.** and Santoro, A.: A randomized comparison of Ceftazidime (Cef) vs Cephalothin, Carbenicillin and Gentamicin (KCG) in Febrile (F+) granulocytopenic (G+) cancer patients (pts.) American Society of Clinical Oncology, San Diego, California, Volume 2, May 1983.
16. **Rand, K.** and Houck, H.: Antibodies to normal cultured human foreskin epithelial cells: Appearance associated with primary cytomegalovirus infection in renal transplant patients. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, California, October, 1983.
17. **Rand, K.** and Swingle, H.: Rotazyme assay for rotavirus in neonates. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 1984.
18. Ramphal, R.; Kramer, B.S.; **Rand, K.H.** and Peeler, U.: A randomized comparison of Ceftazidime (C) vs. Cephalothin, Gentamicin, Carbenicillin (KGC) vs. Ceftazidime plus Vancomycin (CV) in Febrile (F+) Granulocytopenic (G+) cancer patients (pts). 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., October 1984.
19. **Rand, K.**; Houck, H. and Dickinson, M.: High frequency of false positive indirect fluorescent antibody (IFA) reactions to Herpes Simplex Virus - 1 (HSV-1) in a commercial kit. 85th Annual Meeting of the American Society for Microbiology.
20. **Rand, K.**; Bodor, N.; Miyake, A.; Raad, I.; Elkoussi A.A.; Houck, H. and Gildersleeve, N.: Potential treatment of Herpes Simplex Encephalitis (HSE) by brain-specific delivery of Trifluorothymidine (TFT) using a dihydropyridine pyridinium type redox delivery system. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy.

21. **Rand, K.**; Houck, H. and Panfili, P.R.: Cytomegalovirus (CMV) IgM Antibody Determination: Comparison of the Enzygnost^R ELISA with Immunofluorescence (IFA). 86th Annual Meeting of the American Society for Microbiology, Washington D.C., March 1986.
22. Sherertz, R.J.; Belani, A. and **Rand, K.H.**: Relationship between Sonication Vascular Catheter Cultures and Same-Day Blood Cultures. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1986.
23. Raad, I., **Rand, K.**, El Koussi, A.A., Houck, H., Brey, W., Rocca, J. and Bodor, N.: Accumulation of Trifluorothymidine (TFT) in the Livers of Herpes Simplex Virus-2 (HSV-2) Infected Mice. Potential Non-Invasive Detection Using Fluorine Nuclear Magnetic Resonance Spectroscopy. 87th Annual Meeting of the American Society for Microbiology, Atlanta, Georgia, March 1-6, 1987.
24. Houck, H. and **Rand, K.**: Potential interference with enzyme immunoassay for Rotavirus and Reovirus by protease activity in stool. 88th Annual Meeting of the American Society for Microbiology, Miami Beach, Florida, May 8-13, 1988.
25. **Rand, K.**, Elfenbein, G. and Babington, R.: Pharmacokinetics of Cytomegalovirus-specific antibody following intravenous immunoglobulin in bone marrow transplant patients. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, October 4-7, 1987.
26. **Rand, K.**, Ganju A., Houck, H., Babington, R. and Elfenbein, G.: Pharmacokinetics of cytomegalovirus specific IgG and total IgG following intravenous immunoglobulin in bone marrow transplant patients. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 24-26, 1988.
27. Ramphal, R., Oblon, D., Sherertz, R.J., **Rand, K.H.**, Shands J.W., et al.: Should vancomycin be combined with ceftazidime as empiric therapy in febrile neutropenic patients (F+G)? 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 24-26, 1988.
28. **Rand, K.H.** and Farmer, R.: Novel method to measure antibiotic synergy. 89th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May 14-18, 1989.
29. **Rand, K.H.** and Houck, H.: Bacterial DNA contaminates Taq Polymerase. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, September 12-20, 1989.
30. Raad, I., **Rand, K.** and Gaskins, D.: Isolation of Brucella on Buffered Charcoal Yeast Extract Media. 90th American Society for Microbiology, Anaheim, California, May 13-17, 1990.

31. H. Houck and **Rand, K.**: Synergy and Additivity of Aztreonam (A) or Imipenem (I) with Tobramycin (T): Concentration Dependence. 91st American Society for Microbiology, Dallas, Texas, May 5-9, 1991.
32. **Rand, K.** and H. Houck: Identification of Bacterial DNA contaminating Taq Enzyme. 91st American Society for Microbiology, Dallas, Texas, May 5-9, 1991.
33. **Rand, K.H.**, Gibbs, K., Derendorf, H., and Graham-Pole, J.: Pharmacokinetics of Intravenous Immunoglobulin (Gammagard^R) in Bone Marrow Transplant Patients. 5th International Conference on Immunopharmacology, Tampa, Florida, May 26-30, 1991.
34. **Rand, K.H.**, H. Houck, and D. Bennett.: Microtiter Checkerboard for Antibiotic Synergy: A Study of Reproducibility. 92nd American Society for Microbiology, New Orleans, LA, May 27-30, 1992.
35. Wolff, M., **K. Rand**, H. Houck.: Polymerase Chain Reaction (PCR) for Diagnosis of Cytomegalovirus (CMV) Hepatitis in Liver Transplant Recipients. 92nd American Society for Microbiology, New Orleans, LA, May 27-30, 1992.
36. **Rand, K.H.** and H. Houck.: Development and Application of Polymerase Chain Reaction (PCR) for the detection of Candida albicans (CA). ICAAC, Anaheim, CA, October 10-15, 1992.
37. Bialkowska-Hobrzanska, W. Zhong, D. Jaskot, B. Law, D. Low, R. Hall, **K. Rand** and O. Hammerberg.: Molecular Characterization of Bloodstream Isolates of Staphylococcus epidermidis. 93rd General Meeting of the American Society for Microbiology, Atlanta, Georgia, May 1993.
38. **Rand, K.H.** and Brown, P: Synergy of Cefoperazone (CFP) and Imipenem (Im) against Methicillin Resistant Staphylococcus Aureus (MRSA). 93rd General Meeting of the American Society for Microbiology, Las Vegas, Nevada, May 1994.
39. Wolff M.A., Houck H., and **Rand K.H.**: Detection of Human Herpesvirus-6 (HHV-6) and Cytomegalovirus (CMV) in liver tissue of Orthotopic Liver Transplant Recipients. 93rd General Meeting of the American Society for Microbiology, Las Vegas, Nevada, May 1994.
40. **Rand, K.H.**: Rejection Criteria for Endotracheal Aspirates in Neonates: Clinical Impact. 96th ASM General Meeting, New Orleans, Louisiana, May 1996.
41. Gaskins, D. and **Rand, K.H.**: Reagent Cost Management in the Use of the Fecal Lactoferrin Latex Agglutination Assay (Leuko-Test, TechLab, Blacksburg, Va). 96th ASM General Meeting, New Orleans, Louisiana, May 1996.

42. Layon, A.J. Wathana, S, Langevin P.B. and **Rand, K.H.**: Further Work on Ventilator Associated Infections and Their Prevention. *Anesthesiology* 85:A224, 1996.
43. Gaskins, D., Kirkman, A.M., Amos, E., **Rand, K.H.**: Comparison of BBL MGIT, Bactec 460 and Lowenstein-Jensen for the Isolation of Mycobacterium Species. 97th ASM General Meeting, Miami Beach, FL, May 1997.
44. **Rand, K.H.**: Are the Oligoclonal Bands (OCBs) in the Cerebrospinal Fluid (CSF) of Patients with Multiple Sclerosis (MS) Directed at Epstein Barr Virus Nuclear Antigen - 1 (EBNA-1)? American Academy of Neurology, Minneapolis, MN, April 1998.
45. **Rand, K.H.** and Houck, H. Identification of Oligoclonal Bands: An Improved Approach. 51st American Academy of Neurology Annual Meeting, Toronto, ON, Canada, April 1999.
46. **Rand, K. H.**, Gaskins D., Houck H., Pittman L., and Hoang-Minh L.B. Laboratory Detection of Methicillin Resistance in coagulase negative Staphylococci (CONS). American Society for Microbiology, 100th Annual Meeting, Los Angeles, CA May 2000.
47. G. Huff, Donnelly, W. and **Rand, K.** Use of the Tissue Gram Stain in the Histologic Diagnosis (HD) of Ventilator Associated Pneumonia (VAP). American Society for Microbiology, 101st Annual Meeting, Orlando, FL May 2001.
48. Hoang-Minh, L.B., **Rand, K.H.**, Gaskins, D., Pittman, L. and Houck, H. Comparison of Methods for Determining the Susceptibility of Pseudomonas aeruginosa to Cefepime. American Society for Microbiology, 101st Annual Meeting, Orlando, FL May 2001.
49. Khunvichae, A., Hirt, M., Karmann, M., Joliff, L. **Rand, K.**, Derendorf, H. A novel indirect response pharmacokinetic/pharmacodynamic model to characterize the effect of faropenem on Streptococcus pneumoniae and Haemophilus influenzae, 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 2001.
50. **Rand, K.**, Gaskins, D., Pittman, L. Candida Susceptibility Testing: will the real MIC please stand up? American Society for Microbiology, 102nd Annual Meeting, Salt Lake, City, Utah, May 2002.
51. **Rand, K.** and Houck, H. Daptomycin Synergy with Rifampin Against Vancomycin Resistant Enterococci (VRE). 40th Annual Meeting of IDSA, Chicago, IL, October 2002.
52. **Rand, K.H.** and Houck, H.J. Daptomycin (Dap) Synergy with Oxacillin (Ox) against Methicillin Resistant Staphylococcus aureus (MRSA). American Society for Microbiology, 103rd Annual Meeting, Washington, D.C., May 2003.

53. Liu, Q., **Rand, K.H.** and Derendorf, H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin- tazobactam combinations 43rd Annual ICAAC, Chicago, September 2003.
54. Liu, Q., **Rand, K.H.** and Derendorf, H. PK/PD Modeling of antiinfective activity and resistance 12th ISAP International Symposium, Chicago, September 2003.
55. Liu, Q., **Rand, K.H.** and Derendorf, H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin- tazobactam combinations 12th ISAP International Symposium, Chicago, September 2003.
56. Khunvichai, A. Hirt, M. Karmann M., Joliff, L. Zdrojewski, I. **Rand, K.** Derendorf H. A novel indirect response PK-PD model to characterize the effect of faropenem on *Streptococcus pneumoniae* and *Haemophilus influenzae* 2003 AAPS Annual Meeting, Salt Lake City, October 2003.
57. **Rand, Kenneth H.** Real Time PCR for Herpes Simplex Virus (HSV) – Can you Justify the Cost? Association for Molecular Pathology 9th Annual Meeting, Orlando, FL November 2003.
58. Netzel, T., Jindani, I, **Rand, K.H.** Use of Syn2190 to Unmask Extended Spectrum β Lactamases (ESBLs) in *E. coli* and *Enterobacter* sp. American Society for Microbiology, 104th Annual Meeting, New Orleans, LA., May 2004.
59. Derendorf, H. Liu, P. **Rand, K.** Obermann, B. Pharmacokinetic-pharmacodynamic modelling of activities of cefpodoxime and cefixime based on in vivo tissue concentrations and in vitro kill curves 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004.
60. Liu, Q. **Rand, K.** Müller, M. Stass, H. Derendorf H. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation of moxifloxacin Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Vail, June 2004.
61. Tillan, M.D. and **Rand, K.H.** Errors in Interpretation of Gram's Stains from Positive Blood Cultures: How Often Do They Occur and Do They Matter? 42nd Annual Meeting of IDSA, Boston, MA 2004.
62. **Rand, K.** Gaskins, D., Pugh, L., Klinker, K. Notification of Potentially Life-Threatening Treatment Failure for Patients with Resistant Gram Negative Rod (GNR) Bacteremia by the Microbiology Laboratory. American Society for Microbiology, 105th Annual Meeting, Atlanta, GA, June 2005.

63. **Rand, K.**, Houck, H., Huff, G., Donnelly, W., Fiandaca, M., Bergeron, E. Peptide Nucleic Acid (PNA) Probes to Define the Etiology of Ventilator Associated Pneumonia (VAP): Time for a new Gold Standard? American Society for Microbiology, 105th Annual Meeting, Atlanta, GA, June 2005.
64. Anton, A, and **Rand, K.**, Improved Recovery of Potentially Clinically Important Bacteria from Sputum of Cystic Fibrosis Patients. American Society for Microbiology, 105th Annual Meeting, Atlanta, GA, June 2005.
65. **Rand, K.H.** and Houck, H.J. RNA polymerase β ($rpo\beta$) Rifampin (Rif) Binding Site Mutations and Cell Bound Rif Levels in Rif Resistant, Vancomycin Resistant *E. faecium* (VRE) with or without Synergy between RIF and Daptomycin (Dap). American Society for Microbiology, 106th Annual Meeting, Orlando, FL. May 2006.
66. Cardona, D. and **Rand, K.H.** Repeat *Clostridium difficile* Toxin A/B Testing Practices. College of American Pathologists (CAP), Chicago, IL., October, 2007.
67. **Rand K.**, Houck H., Gaskins D., Pittman L., Prins C., Fauerbach L., Seifert H., and Gross M. Spread of KPC Carbapenemase-producing *K. pneumoniae* to North Florida. Association for Molecular Pathology, November, 2007.
68. Bradley M Turner MD, MPH and **Kenneth H Rand, MD.** Comparison of Two Phenotypic Screening Methods for the Detection of Blood-Borne AmpC B-Lactamase (AmpC) Producing Isolates. The United States and Canadian Academy of Pathology Annual Meeting, Denver, Colorado, March 2008.
69. **Rand K** and Houck H. Compensatory Mutation does not explain ability of VRE to grow in the presence of Rifampin (R) bound to RNA polymerase (RPO). American Society of Microbiology, 108th Annual Meeting, Boston, MA., June 2008.
70. William G. Farmerie, Jian-Liang Li, Shane Claggett, Li Liu, Savita Shanker, Ernesto Almira, Kevin Holland, Herbert J Houck, and **Kenneth H. Rand.** Building a collaborative environment for supporting clinical translational research using next generation DNA sequencing technology. Advances in Genome Biology and Technology, Marco Island, FL, February 2009.
71. **Kenneth H. Rand**, Howard Rampersaud, and Herbert Houck. Multiplex Respiratory Virus PCR: A Comparison of two Methods with Traditional Virus Culture. Clinical Virology Symposium, Daytona Beach, FL, April 2009.
72. **Rand, K.H.**, Houck, H., Gaskins, D., Giglio, P., Romeo, T. The Double-Life of *Acinetobacter Baumannii*: Gram Negative Wolf in Gram Positive Sheep's Clothing? American Society of Microbiology, Philadelphia, PA, May, 2009.

73. Bovio I., Rampersaud H, and **Rand K.H.** Multiplex PCR Diagnosis of Viral Respiratory infections: Projected Cost Savings and Impact on Patient Admission Length. College of American Pathologists, Washington, DC, October, 2009.
74. **Kenneth H. Rand MD**, Bradley Turner, MD, Hilary Seifert, Christine Hansen, PharmD, and Judith Johnson, PhD. Clinical Laboratory Detection of AmpC: Does it affect patient outcome? Infectious Diseases Society of America, Philadelphia PA October, 2009.